Diagnosis and management of pneumonia in the intensive care unit.
Ventilator-associated pneumonia is a significant contributor to excess morbidity and mortality in the ICU. Alteration of physical defenses, bacterial flora, and immune response contribute to the susceptibility of the critically ill ventilated patient. Controversies regarding its definition continue to complicate the understanding of the extent of the disease and evaluation of the outcome of therapies. Traditional parameters, such as clinical suspicion with standard tracheal aspirates, are associated with overuse of antibiotics, a prime risk factor for development of resistant organisms and increased mortality. Global emergence of resistance is also a major concern. Whether invasive methods have any substantial clinical benefit either through improved patient outcomes or lower rates of resistance remains to be proved. In patients who fail to respond to therapy, a search for nonpulmonary infections and noninfectious causes of pulmonary infiltrates is essential. Finally, preventative measures offer additional areas of investigation that could favorably impact on the incidence of infection.
Cardenas
Victor J
VJ
Division of Pulmonary and Critical Care Medicine and Medical Intensive Care Unit, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0561, USA. vcardena@utmb.edu
D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D004352:Drug Resistance, Microbial; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D011014:Pneumonia / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy; D017211:Treatment Failure
D000900:Anti-Bacterial Agents